<DOC>
	<DOCNO>NCT00544908</DOCNO>
	<brief_summary>RATIONALE : Dasatinib may stop growth tumor cell block enzymes need cell growth . PURPOSE : This phase II trial study well dasatinib work treat patient stage IV pancreatic cancer .</brief_summary>
	<brief_title>Dasatinib Treating Patients With Stage IV Pancreatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To evaluate 4-month progression-free survival ( PFS ) rate patient stage IV pancreatic cancer treat dasatinib . Secondary - To evaluate response rate ( complete partial response ) patient treat drug . - To evaluate median PFS overall survival patient treated drug . - To study toxicity tolerability drug patient . - To evaluate impact drug quality life measure . - To evaluate impact drug Src FAK peripheral blood mononuclear cell prior treatment . - To study pre-treatment expression various signal molecule Src STAT3 pathways attempt identify relationship finding aggressiveness tumor response treatment dasatinib . OUTLINE : This multicenter study . Patients receive oral dasatinib twice daily day 1-28 . Courses repeat every 28 day absence disease progression unacceptable toxicity . Patients undergo tumor tissue blood sample collection periodically correlative biological study . Blood sample analyze phosphorylation level protein , include phospho-Src , phospho-Fak , relevant biomarkers , western blotting . Tumor tissue sample analyze biomarkers immunohistochemistry . Quality life assess baseline , every course treatment , 1 year treatment use FACT-HEP questionnaire . After completion study treatment , patient follow every 2 month .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically* confirm pancreatic cancer Stage IV disease NOTE : *If biopsy perform outside facility , histology must review confirmed Division Pathology City Hope PATIENT CHARACTERISTICS : Karnofsky performance status 60100 % Life expectancy ≥ 3 month Platelet count ≥ 100,000/μL Absolute neutrophil count ≥ 1,500/μL Bilirubin ≤ 1.5 mg/dL ALT AST ≤ 2.5 time upper limit normal ( ULN ) Creatinine ≤ 1.5 mg/dL and/or creatinine clearance &gt; 60 mL/min PT PTT ≤ 1.5 time ULN Able swallow dasatinib whole No malignancy within past 5 year except nonmelanoma skin cancer carcinoma situ cervix , uterus , bladder No concurrent medical condition may increase risk toxicity , include follow : Pleural pericardial effusion grade Clinically significant coagulation platelet function disorder ( e.g. , know von Willebrand 's disease ) None follow cardiac condition : Uncontrolled angina , congestive heart failure , myocardial infarction within past 6 month Prolonged QTc interval ( i.e. , QTc &gt; 450 msec ) electrocardiogram History clinically significant ventricular arrhythmia ( i.e. , ventricular tachycardia , ventricular fibrillation , Torsades de pointes ) No hypokalemia hypomagnesemia correct No severe infection require treatment Completely recover concurrent illness , deem investigator Not pregnant Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Recovered prior major surgery No prior irradiation plan field No prior chemotherapy pancreatic cancer At least 7 day since prior concurrent medication may prolong QT interval , include follow : Quinidine Procainamide Disopyramide Amiodarone Sotalol Ibutilide Dofetilide Erythromycin Clarithromycin Chlorpromazine Haloperidol Mesoridazine Thioridazine Pimozide Cisapride Bepridil Droperidol Methadone Arsenic Chloroquine Domperidone Halofantrine Levomethadyl Pentamidine Sparfloxacin Lidoflazine At least 7 day since prior concurrent potent CYP3A4 inhibitor At least 7 day since prior concurrent medication directly durably inhibit platelet function , include follow : Aspirin aspirincontaining combination Clopidogrel Dipyridamole Tirofiban Dipyridamole Epoprostenol Eptifibatide Cilostazol Abciximab Ticlopidine Cilostazol No concurrent anticoagulant , include warfarin heparin/low molecular weight heparin ( e.g. , danaparoid , dalteparin , tinzaparin , enoxaparin ) Lowdose warfarin prophylaxis prevent catheter thrombosis heparin flush IV line allow No concurrent IV bisphosphonates first 8 week dasatinib therapy No concurrent Hypericum perforatum ( St. Johns wort )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>stage IV pancreatic cancer</keyword>
</DOC>